HIV co-receptor inhibitors as novel class of anti-HIV drugs

被引：31

作者：

Schols, Dominique ^{[1
]}

机构：

[1] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium

来源：

ANTIVIRAL RESEARCH | 2006年 / 71卷 / 2-3期

关键词：

CCR5; CXCR4; antagonist; HIV; chemokine receptor; gp120; envelope; HUMAN-IMMUNODEFICIENCY-VIRUS; CHEMOKINE RECEPTOR CXCR4; SMALL-MOLECULE INHIBITOR; HUMAN LYMPHOID-TISSUE; INFECTION IN-VITRO; TYPE-1; REPLICATION; CCR5; ANTAGONIST; HIGHLY POTENT; TROPIC HIV-1; SELECTIVE-INHIBITION;

D O I：

10.1016/j.antiviral.2006.04.009

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Entry inhibitors constitute a new class of drugs to treat infection by human immunodeficiency virus type 1 (HIV-1). The first member of this class, enfuvirtide, previously known as T-20 and targeting gp41, has now been licensed for therapeutic use. Several other entry inhibitors are in various stages of pre-clinical or clinical development. In this review we focus on the chemokine receptor inhibitors targeting CCR5 and CXCR4 that are the main HIV co-receptors for viral entry. (c) 2006 Elsevier B.V. All rights reserved.

引用

页码：216 / 226

页数：11

共 97 条

[71]

REYNES J, 2002, 9 C RETR OPP INF SEA, P53

[72]

REYNES J, 2002, 9 C RETR OPP INF FEB

[73] Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene [J].

Samson, M ;

Libert, F ;

Doranz, BJ ;

Rucker, J ;

Liesnard, C ;

Farber, CM ;

Saragosti, S ;

Lapoumeroulie, C ;

Cognaux, J ;

Forceille, C ;

Muyldermans, G ;

Verhofstede, C ;

Burtonboy, G ;

Georges, M ;

Imai, T ;

Rana, S ;

Yi, YJ ;

Smyth, RJ ;

Collman, RG ;

Doms, RW ;

Vassart, G ;

Parmentier, M .

NATURE, 1996, 382 (6593) :722-725

[74] In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression [J].

Scarlatti, G ;

Tresoldi, E ;

Bjorndal, A ;

Fredriksson, R ;

Colognesi, C ;

Deng, HK ;

Malnati, MS ;

Plebani, A ;

Siccardi, AG ;

Littman, DR ;

Fenyo, EM ;

Lusso, P .

NATURE MEDICINE, 1997, 3 (11) :1259-1265

[75] System integration of microsystems chip elements in miniaturized automata for high-throughput synthesis and screening in biology, biochemistry and chemistry [J].

Schober, A ;

Schlingloff, G ;

Thamm, A ;

Kiel, HJ ;

Tomandl, D ;

Gebinoga, M ;

Doring, M ;

Kohler, JM ;

Mayer, G .

MICROSYSTEM TECHNOLOGIES, 1997, 4 (01) :35-39

[76] CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity [J].

Schols, D ;

Proost, P ;

Struyf, S ;

Wuyts, A ;

De Meester, I ;

Scharpé, S ;

Van Damme, J ;

De Clercq, E .

ANTIVIRAL RESEARCH, 1998, 39 (03) :175-187

[77] Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4 [J].

Schols, D ;

Struyf, S ;

VanDamme, J ;

Este, JA ;

Henson, G ;

DeClercq, E .

JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (08) :1383-1388

[78] T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1α contains mutations in the envelope gp120 but does not show a switch in coreceptor use [J].

Schols, D ;

Esté, JA ;

Cabrera, C ;

De Clercq, E .

JOURNAL OF VIROLOGY, 1998, 72 (05) :4032-4037

[79]

SCHOLS D, 2003, 10 C RETR OPP INF BO, P257

[80]

SCHOLS D, 2002, 9 C RETR OPP INF FEB

← 1 2 3 4 5 6 7 8 9 10 →